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Keratoconjunctivitis sicca (KCS), the deficiency of tears also known as dry eye, is a 
prevalent disease that affects both humans and canines. The current treatment for dye eye, 
cyclosporine (Restatis®), only provides temporary relief, is often associated with 
discomfort and is inconsistently effective. Lacritin is a naturally occurring tear glycoprotein 
secreted from the human and canine lacrimal glands. It has been shown that lacritin 
stimulates basal tearing in rabbits when applied topically. This study characterized the 
amount and form of lacritin found in the tears of dogs with healthy and dry eyes—
information which may be applied to the development of a lacritin-inspired therapeutic for 
humans and canines. In collaboration with the Virginia-Maryland College of Veterinarian 
Medicine, tear samples were collected from dogs being treated at the veterinary clinic and 
transported to JMU for analysis. At JMU, the lacritin and other proteins found in the canine 
tears were analyzed by indirect Enzyme-Linked Immunosorbent Assay (ELISA), SDS-
Polyacrylamide Gel Electrophoresis (SDS-PAGE), and western blot. A total of 64 tear 
samples were analyzed with 32 samples from healthy dogs and 32 samples from dogs 
clinically diagnosed with dry eye.  ELISA revealed that canines with KCS had a significant 
decrease in tear lacritin.  Western blot analysis detected prominent bands in healthy tears 
at approximately 18 kDa (corresponding to monomeric canine lacritin) that were absent or 
faintly observed in tears from dry eye dogs.  This study provides clinical data reinforces the 















Keratoconjunctivitis sicca (KCS), the deficiency of tears also known as dry eye, is a 
prevalent disease that affects both humans and canines.  Symptoms include dry, burning, 
itchy, scratchy, stingy, or tired eyes (Merck Manual, 2003).   Dry eye is the most common 
eye disease, affecting the quality of life of over 25 million Americans, especially women and 
the geriatric population (Seifert et al., 2012). Blepharitis is a complex inflammation of the 
eyelid associated with dry eye and meibomian gland dysfunction.  Next to dry eye, it is one 
of the most common conditions seen by ophthalmologists. The current treatment for dye 
eye, cyclosporine (Restatis®), increases tear production, but only provides temporary 
relief. Additionally, some people have little or no effective reaction to the medication (Ofria 
et al., 2009). A proteomics study recently discovered certain tear proteins were selectively 
down-regulated in tears of patients suffering from chronic blepharitis and dry eye (Koo et 
al., 2005).  Down-regulation of naturally occurring tear proteins may provide biomarkers 
for the diagnosis of ocular diseases and replacement therapeutic treatments for these 
disorders.  
Lacritin is a naturally occurring human tear glycoprotein discovered and first 
characterized by Gordon Laurie at the University of Virginia as a novel secretion enhancing 
factor from the human lacrimal gland (Sangi et al., 2001).  It is a prosecretory mitogen that 
consists of 119 amino acids and is 12.3 kDa in size produced by the lacrimal gland that exits 
the gland through acinar secretory granules and flows through ducts to the surface of the 
eye (Ma et al., 2008).  It has been found that when lacritin is bound to corneal epithelial 
cells, it stimulates the lacrimal gland to produce tears (Sanghi et al., 2001).  The down-
regulation of lacritin has been found in patients with blepharitis (Tsai et al., 2006) and 
lacritin is the only prosecretory protein that is down-regulated in patients suffering from 
dry eye (Srinivasan et al., 2012).  Preclinical animal studies have shown that recombinant 
human lacritin produced in Escherichia coli promotes basal tearing in rabbit eyes upon 
topical application (Samudre et al., 2011).  Recently, a prototype clinical assay to quantify 
lacritin in human tear samples was developed (Seifert et al., 2012) and used to detect a 
lacritin-like protein in horse tears (Laurie et al., 2012).  In addition, it was shown that a 
cleavage potentiated C-terminal fragment of lacritin is bactericidal against Gram positive 
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and Gram negative ocular pathogens (McKown et al., 2014). Taken together, these 
observations suggest that tear lacritin may be an influential ocular surface protector. 
KCS is a common ophthalmic disease in dogs, with the recent literature citing a 
prevalence of 4% in the general canine population (Williams et al., 2008).  Canine KCS can 
occur for a variety of reasons, the most common being decreased aqueous tear production 
from immune-mediated inflammation of the lacrimal gland (Williams et al., 2008).  As such 
lifelong therapy is typically necessary.   
A consortium of researchers from James Madison University (JMU), the University of 
Virginia (UVa), Walter Reed Army Medical Center, Eastern Virginia Medical School, and 
other institutions investigate lacritin as a potentially new human therapeutic for the 
treatment of dry eye.  With support from the 4-VA Collaborative, a new JMU—Virginia-
Maryland Regional College of Veterinary Medicine collaboration was initiated in 2012 to 
study the role of lacritin in canine dry eye.  As a result, a lacritin-like protein was detected in 
canine tear samples by human anti-lacritin antibodies.  With scale-up funding from 4-VA, 
the gene encoding the canine lacritin ortholog was cloned, sequenced, and a recombinant 
form was expressed and purified in E. coli. Antibodies specific to canine lacritin were 
produced and a canine Enzyme-Linked Immunosorbent Assay (ELISA) was developed.  
Preliminary results of this assay have revealed that canine lacritin is down-regulated in 
tears from dogs with dry eye.    
Summary of Previous Work 
Summary of Work Accomplished by Alan C. Tate, Honors Thesis, 2014 
 
Tear samples collected at Virginia-Maryland Regional College of Veterinary 
Medicine were shipped to JMU for analysis.  Total protein was eluted from the wicks by 
means of centrifugation and total protein concentrations were determined by a 
bicinchoninic acid (BCA) assay.  An ELISA, previously developed at JMU to detect human 
lacritin, was used to quantify lacritin in dog tears.   Recombinant human lacritin was used as 
a protein standard in the assay. Of the two anti-lacritin human polyclonal antibodies tested, 
the one directed towards the N-terminus was the most effective at detecting canine lacritin 
in the samples.  Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
western blots were performed on the canine samples using the human antibodies. Forms of 






Figure 1. SDS-PAGE and western blot analysis of canine tears.  (A) Tear samples 1, 5, 6, and 10 
were separated by SDS-PAGE and visualized with Coomassie blue stain.  A molecular weight standard 
is shown on the far left of the gel.  Approximate band sizes are labeled.  (B) Tear samples 5, 6, 9 and 
10 were separated by SDS-PAGE, transferred to nitrocellulose, incubated with anti-N-terminal 
hlacritin antibodies, and detected by chemiluminescence.  “Hu Tears” refers to a control human tear 
sample.  “OD” and “OS” refer to samples taken from the right versus left eye from an individual, 
respectively (Tate, Honors Thesis 2012).   
 
In order to make recombinant canine lacritin, total RNA was extracted from normal 
canine lacrimal glands, reverse transcribed (using gene-specific primers?) and PCR 
amplified.  The resulting cDNA was cloned into the bacterial expression vector, pTYB2. 
Recombinant canine lacritin was expressed in E. coli and purified by chitin affinity column 
and diethyl-aminoethyl (DEAE) chromatography (Figure 2).  
A B 




Figure 2. RT-PCR of canine lacritin gene, purification of recombinant canine lacritin, and DEAE 
chromatography elution profile. (A) Agarose DNA gel of the RT-PCR product.  Lane 1 contains the 
100 bp DNA ladder, with fragment sizes indicated.  Lane 2 contains the amplified PCR product of the 
canine lacritin cDNA.  (B) SDS-PAGE gel of 18 kD purified recombinant canine lacritin.  Lane 1 
contains the molecular weight standards, lane 2 contains the cleared cell lysate prior to chitin affinity 
chromatography, lane 3 contains the fraction extracted after chitin affinity chromatography, and lane 
4 contains the eluted sample from the DEAE Sepharose column.  (C) DEAE chromatography elution 
profile of recombinant canine lacritin.  Following chitin affinity chromatography, protein fractions 
were pooled, dialyzed in 14 mM NaCl PBS, and loaded onto a DEAE sepharose column equilibrated 
with 14 mM NaCl PBS, pH 7.4.  The column was eluted with 140 mM PBS and 500 mM NaCl PBS cuts.  
Protein concentrations of each fraction were determined using PierceTM BCA Protein Assay Kit (Tate, 
Honors Thesis 2012). 
 
Summary of Work Accomplished by Alison M. Enghauser, Honors Thesis, 2015 
Anitbodies directed against the N- terminus of canine lacritin were produced and 
purified. The N-terminus peptide of canine lacritin EGDSSDPAPGAAAADPGGL was 
synthesized with >90% purity and conjugated to keyhole limpet hemocyanin/bovine serum 
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albumin (KLH/BSA) by Bio-Synthesis, Inc. (Lewisville, TX). Two New Zealand white rabbits, 
designated 6924 and 6925, were immunized and serum was collected over a 10 week 
period. Preimmune serum was collected before immunization and final antiserum was 
collected after 10 weeks. Protein A coupled with agarose beads (Bio-Rad Laboratories; 
Hercules, CA) was used to purify IgG antibodies from the anti-cLACRT NT antiserum.  An 
indirect ELISA was used to titrate the anti-cLACT NT canine antibodies.  
A preliminary study of canine tear lacritin was performed using the anti-cLACRT 
antibodies. Canine tear samples were obtained at the VA-MD Regional College of Veterinary 
Medicine at Virginia Tech, eluted off the wicks and total tear protein determined by a BCA 
assay.  An indirect ELISA and western blot was used to quantify lacritin in healthy and dry 
eye canine tear samples. The ELISA was developed using 10 week anti-cLACRT NT PA 
purified antiserum (from rabbit 6924) as the primary antibody and the HRP-conjugated 
antibody as the secondary.  A summary of lacritin concentrations in canine tear samples is 
shown in Figure 3, and western blot analysis in Figure 4. This work showed that the anti 
lacritin serum can successfully detect canine lacritn, as well as showing preliminary 
evidence that lacritin may be down regulated in the tears of canines with dry eye.  
 
 
Figure 3. Lacritin concentrations in canine tears, as determined by indirect ELISA using anti-
cLACT NT primary antiserum. “OD” and “OS” refer to samples taken from the right versus left eye 
from an individual, respectively.  The origin of each sample is indicated: normal (blue, “N”) or dry eye 




Figure 4. Western blot analysis of normal (1) and dry eye (66, 59, 44) tears from canine 
samples.  A standard molecular weight ladder, with kilo-Dalton (kDa) band sizes indicated, is shown 
on the left.  “OD” and “OS” refer to samples taken from the right versus left eye from an individual, 
respectively.  The band corresponding to monomeric canine lacritin is seen at ~18 kDa (arrowhead). 
Bands with larger molecular weights represent cross-linked variations of lacritin . (Enghauser et. al., 
















METHODS AND MATERIALS 
Tear Collection and Elution 
 
Dr. Julie Disney, a resident in Ophthalmology at the Virginia-Maryland Regional 
College of Veterinary Medicine at Virginia Tech, collected canine tear samples from 64 
animals—32 from healthy and 32 dry eye dogs.  Wicks were placed on each of the the 
canine’s eyes to absorb tears. Samples were eluted by placing 30 μL of filter sterilized 
phosphate buffered saline (PBS) onto each wick, incubateding for 20 minutes, followed by 
centrifugation for 5 minutes at 13,000 rpm.  Supernatants were collected as eluted tear 
samples and stored at -20° C.  
 
Total Tear Protein Concentration 
 
To determine the total tear protein concentration in each canine tear sample, the 
Thermo Scientific BCA Protein Assay Kit (Waltham, MA, USA) was used, as recommended by 
the manufacturer. Bovine serum albumin (BSA) Standards ranging from 20 to 2000 µg/mL 
and experimental samples were analyzed in duplicate in a 96-well microtiter plate following 
incubation for 30 minutes at 37° C. The plates were read at 570 nm in a spectrometer. The 
standard protein concentrations were graphed versus the absorbance values and a line of 
best fit was determined. Based on the equation of the line of best fit, each sample’s total tear 
protein concentration was calculated.    
 
Indirect ELISA Assay 
 
The purpose of the indirect ELISA was to quantify the lacritin concentration in each 
canine tear sample. The indirect ELISA comprised of two components, the standard curve 
and the experimental samples. To create the standard curve, lyophilized recombinant 
canine lacritin (cLAC) was resuspended with 100 μL of deionized water, diluted with 
coating buffer (4.53 mL of 1.0 M NaHCO3, 1.82 mL of 1.0 M Na2CO3, 93.65 mL dH2O) and 
coated onto a 96-well microtiter plate with final concentrations of 0, 2, 4, 6, 8, 10, 12, 14, 
and 16 ng/mL. 100 μL of each standard was plated in triplicate.   
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The experimental samples were diluted with coating buffer to normalize the total 
tear protein to 0.5 μg/mL and 100 μL was added in triplicate to the plate. Samples were 
divided into eight sets of eight, such that each 96-well plate held eight samples. Each plate 
had a mix of both normal and dry eye samples, Duplicate plates were performed for ELISA 
analysis. All samples underwent the same procedure, as follows: 
Plates were incubated overnight at 4°C, then washed three times with PBS/0.3% 
Tween-20 (PBST).  Three hundred microliters of blocking buffer (1% w/v BSA) was 
applied to the wells. The plates were then incubated at 37°C for one hour. Following 
incubation, the plates were washed three times with PBST and then 100 μL of the primary 
antibody (6924 FB PANT) diluted 1:6400 in PBST was applied to each well. The plates were 
incubated again at 37°C for one hour. Next the plates were washed three times with PBST 
and 100 μL of the secondary HRP-conjugated goat anti-rabbit IgG antibody (Company or 
source) diluted 1:1200 in PBST was applied to each well.  The plates were incubated for a 
third time at 37°C for one hour. Next the plates were washed three times with PBST and 
100 μL of the o-phenylenediamine dihydrochloride (OPD) substrate was added. The OPD 
substrate was prepared by combining 6.0 mL of 0.1 M C6H8O7, 6.5 mL of 0.2 M Na2HPO4, 
12.5 mL dH2O, 10 μL H2O2, and two OPD tablets (Acros Organics, Geel, Belgium).  Plates 
were incubated in the dark for 10 minutes then read in the spectrophotometer at 415 nm. 
The absorbances of the known recombinant canine lacritin solutions were plotted against 
their concentration and a standard curve with a best-fit line was generated. The absorbance 
values of the experimental samples were used in the best-fit line to determine lacritin 
concentrations.  
 
Antibody Specificity and Titrations 
 
Final bleed N-Terminal Protein A-purified (PANT FB) antibodies from rabbit 6924 
were titrated against known concentrations of recombinant canine lacritin to determine 
their specificity and optimal dilutions for the standard curve for the ELISA. Recombinant 
canine lacritin was diluted from 0.1 to 1000 ng/mL in coating buffer and 100 μL were 
applied to the wells of a 96-well microtiter plate. The 6924 PANT FB antibodies were 
diluted in PBST from 1:200 to 1:12800 and 100 μL were added to the wells and the 
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secondary HRP-conjugate goat anti-rabbit IgG antibody was diluted to 1:800 in PBST and 
100 μL were added to each well.  
A checkerboard titration was performed to optimize the dilutions of the primary 
and secondary antibody refine the dilutions determined by the titration and determine the 
optimal dilution for the secondary antibody. Canine lacritin was diluted from 1.5 to 20 
ng/mL in coating buffer and plated. 6924 PANT FB primary antibodies were diluted to 
1:400 in PBST and the secondary HRP-conjugated antibody was diluted from 1:200 to 
1:12800 in PBST and applied to the plate and developed using the standard ELISA protocol.  
SDS Polyacrylamide Gel Electrophoresis and Western Blots 
 
Western blots were used to visually detect lacritin in the canine tear samples. 
Samples were diluted in PBS to 200 μg/mL and 20 μL was added to the wells.  4 μL of 6x 
loading dye was added. Ten microliter  aliquots of the prepared samples were boiled for 5 
minutes, and then loaded—along with 7 μL of the protein ladder (Precision Plus Protein 
Kaleidoscope Standards, BioRad)—into an Any kD™ Mini-PROTEAN® TGX™ Precast Gel 
(Bio-Rad, ADD LOCATION) filled with Tris-glycine buffer and run at 200 volts until the 
samples reached the bottom of the gel.  Proteins were then transferred onto a nitrocellulose 
membrane for western blotting. A Mini Trans-blot (COMPANY?), run for 60 minutes at 100 
V, was used to transfer the samples from the gel to the membrane. The membranes were 
removed from the apparatus, wrapped in aluminum foil, and stored at 4°C overnight. 
 The blotted membranes underwent four 10-minute washes with PBST, and then 
incubated with the 1:1,000 dilution of primary antibody (6924 FB PANT) in PBST for one 
hour at room temperature.  Next the membranes underwent four 10-minute washes in 
PBST, followed by a one hour incubation with the 1:5,000 dilution of secondary HRP-
conjugated goat anti-rabbit IgG antibody in PBST. The membranes were then washed twice 
with PBST for 15 minutes each, followed by two 15-minute washes of PBS, then air-dried.  
Blots were detected by chemiluminescence with Pierce ECL Western Blotting 
Substrate (Thermo Fisher Scientific Inc., Rockford, IL), according to the manufacturer’s 
recommendations.  Membranes were soaked in substrate for one minute and covered in 
clear plastic wrap. Chemiluminescence was detected by X-ray film.  Exposed film was 
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dipped in developer solution, deionized water, fixer solution and deionized water (30 
























Total Tear Protein Concentration 
 
A BCA assay was used to determine the total protein concentrations of the dry eye 
and normal tear samples.  Dry eye protein concentrations ranged from 367.1-7655 µg/mL, 
with a median of 1433.5 µg/mL, and an average of 2127 µg/mL. Normal protein 
concentrations ranged from 550.6-2485 µg/mL, with a median of 1323 µg/mL, and an 
average of 1379 µg/mL.  All BCA assays had standard curves with R2 values above 0.98. 
Figure 5 shows a representative standard curve. Results from the dry eye and normal 
samples are shown in Table 1 and Table 2, respectively. Raw data are shown in Appendix A.  
 



























Table 1. Summary of total tear protein in dry eye canines. The eye of origin 
(OD or OS) and concentration of each sample is indicated. Samples are listed 
in ascending order of average (left and right) total protein 
concentration. 













OS 503.3 OS 1165 




















OS 1137 OS 2968 
135100 OD 1347 
134989 
OD 4055 
131139 OS 1433 OS 2956 



















Table 2. Summary of total tear protein in normal canines. The eye of origin 
(OD or OS) and concentration of each sample is indicated. Samples are listed 
in ascending order of average (left and right) total protein 
concentration. 













OS 852.6 OS 1577 




























OS 1311 OS 2015 
131139 OD 1273 135100 OS 2485 
87637 
OD 1520 
   OS 1262 
    
 
 
Antibody Specificity and Titrations 
A titration was performed on 6924 PANT FB to determine its specificity for 
recombinant canine lacritin and the optimal dilution for indirect ELISA. Dilutions of 
recombinant canine lacritin and the 6924 primary antiserum were created and used in a 
series of indirect ELISAs. The titration curve indicates that the antibodies detect lacritin at 




Figure 6. Titration of 6924 antibodies. A titration curve of antibody 6924 PANT FB where Lacritin 
was diluted from 0.1 to 1000 ng/mL and the primary antibody 6924 was diluted from 1:200 to 
1:12800.  The titration curve indicates that the antibodies can detect lacritin at concentrations 
greater than 0.1 ng/mL and that there is saturation of the assay at 100 ng. 
 
A checkerboard titration was performed on the primary antibody 6924 PANT FB to 
determine the optimal dilutions of the primary and secondary for the standard curve 
(Figure 7). Lacritin was diluted to 1.5 to 20 ng/mL, the primary antibody 6924 PANT FB 
was diluted to 1:400 and the secondary antibody was diluted from 1:200 to 1:12800. Based 
on the titrations, the optimal dilution of the primary antibody was 1:6400 and the 





























Figure 7. Checkerboard titration of 6924 antibodies. A checkerboard titration where lacritin was 
diluted from 1.5 to 20 ng/mL, the primary antibody was diluted to 1:400 and the secondary antibody 
was diluted from 1:200 to 1:12800.   
 
Indirect ELISA Assay 
An indirect ELISA was used to quantify lacritin in each tear sample. The assay was 
developed using 10 week Protein A purified anti-cLACRT NT antiserum from rabbit 6924 as 
the primary antibody and HRP-conjugated anti-rabbit secondary antibody. All standard 
curve R2 values were above 0.96. Samples were run in triplicate with a standard curve done 
in duplicate plates. Due to technical limitations of the assay, 16 ng lacritin/50 ng total 
protein is the highest concentration that can be detected without extrapolation. Thus, 
samples that had concentrations higher than 16 ng lacritin are categorized as 16 ng or 
greater.  
Lacritin concentrations in the 32 dry eye samples ranged from 0-16 ng /per 50 ng 
total tear protein (median 4.38 ng/50 ng total; average 5.80 ng/50 ng total). The range of 
lacritin in the normal samples was 2.32-16 ng lacritin per 50 ng total tear protein (median 
14.83 ng/50 ng total; average 13.29 ng/50 ng total). Figure 8 shows a representative 
standard curve generated from indirect ELISA. Tables 3 and 4 show summaries of the 
lacritin concentrations in the dry eye and normal canines, respectively.  Raw indirect ELISA 


























Figure 8.  Standard Curve using 6924 antibodies. An example of a standard curve of canine lacritin 




































Table 3. Summary of lacritin concentrations in dry eye canines The eye of 
origin (OD or OS) and concentration of each sample is indicated. Samples are 
listed in ascending order of average (left and right) lacritin concentration. 
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Lacritin             
















OS 0.0 OS 16.0 
137185 OS 0.0 
134668 
OD 15.9 
102059 OS 0.0 OS 0.0 
92935 




134564 OD 1.7 OS 13.5 
114039 
























Table 4. Summary of lacritin concentrations in normal canines. The eye of 
origin (OD or OS) and concentration of each sample is indicated. Samples are 
listed in ascending order of average (left and right) lacritin concentration. 




Lacritin             





Lacritin             
(ng/ 50 ng 
total protein) 




OD 16.0 OS 16.0 





OS 16.0 OS 13.9 
121747 





























A western blot was performed to visually detect lacritin concentration. Anti-cLACRT 
NT PA purified antiserum from rabbit 6924 was used as the primary antibody and HRP-
conjugated antibody was used as the secondary antibody. Normal samples produced a 
prominent band at 18 kDa.  This band was fainter, or absent, in dry eye samples. Western 





Figure 9. Western blot analysis of dry eye and normal samples. Western blot analysis of the 
samples with their Schirmer Tear Test (STT) values and lacritin concentrations, as determined by 
indirect ELISA. An STT value below 15 indicates dry eye, while values above indicate normal tearing 
levels. The band corresponding to monomeric canine lacritin is seen at ~18 kDa. Higher molecular 
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weight moeities are cross-linked variations of lacritin. D = Dry eye tear samples and N = Normal tear 
samples.  Lacritin values are ng per 50 ng total tear protein as determined by the ELISA.   
 
To better understand these western blot data, one must compare it to the Schirmer 
Tear Test (STT) values. A STT is a test used to measure tearing levels in both dogs and 
humans to help diagnose dry eye. For canines, any value under 15 indicates dry eye and any 
value above 15 indicates normal tearing. A scatter plot showing the correlation between 
total tear protein and STT values is shown is shown in Figure 10, and a scatter plot showing 
the correlation between lacritin concentration and STT values is shown in Figure 11.   
 
 
Figure 10. Dry eye and normal total tear protein as a function of STT values. A scatter plot 
showing the total tear protein of the normal and dry eye samples. An STT value is a measure of 
tearing in the eyes and a value below 15 indicates dry eye and a value above 15 indicates normal 





































Figure 11. Dry eye and normal lacritin concentrations as a function of STT values. A scatter plot 
showing lacritin concentration as determined by the ELISA as a function of STT values in the dry eye 
and normal samples. An STT value is a measure of tearing in the eyes and a value below 15 indicates 
dry eye and a value above 15 indicates normal tearing levels. The bar in the middle of each cluster of 




























































In this clinical study, 64 samples of canine tears, 32 dry eye and 32 normal, were 
collected at the VA-MD Regional College of Veterinary Medicine at Virginia Tech by Dr. Julie 
Disney. The samples were sent to JMU and assayed for total tear protein by BCA assay and 
lacritin concentration by indirect ELISA.  Lacritin was visually detected in samples using a 
western blot.  
According to this study, canines with dry eye had variable total tear protein levels, 
ranging from 367.1-7655 µg/mL with a standard deviation of 1737.5 µg/mL, while the 
normal tears had consistent total tear protein values between 550.6-2485 µg/mL with a 
standard deviation of 403.8 µg/mL (Figure 10). The three highest dry eye samples (7655, 
7018 and 4807 µg/mL) were collected from canines that are non-responsive to clinical 
treatment for dry eye. It is possible that their treatment may have stimulated excessive tear 
protein production, explaining the atypically high concentrations. It is also possible that 
canines with dry eye produce more tear proteins in an attempt to compensate for their 
condition.  
Lacritin concentrations were reduced in dry eye samples compared to normal samples 
(Figure 11). Dry eye samples had an average of 5.8 ng and a standard deviation of 4.3 ng 
lacritin per total ng protein while normal samples had an average of 13.3 ng and a standard 
deviation of 3.8 ng lacritin (Figure 11).  Interesting to note, the three highest dry eye total 
tear protein samples mentioned above had undetectable levels of lacritin by ELISA. Thus 
although these animals high total concentrations of tear proteins, lacritin is absent, which 
may be correlated with their lack of response to treatments.  Variability within the sample 
set can be expected in a clinical study incorporating many different breeds, ages, and 
genders of canines.  It is also important to note that samples were collected from canines 
during diagnosis or treatment of dry eye.  Such variability in clinical progression can also 
explain variation within the data set.  
Another point of interest is that some of the western blots detect lacritin complexes 
greater than 18 kDa. This indicates that the anti-canine LAC antibody is detecting a cross-
linked lacritin. It has been shown that tissue transglutaminase cross-links (human?) lacritin 
and forms higher molecular weight complexes that appear above ~18 kD on western blots 
(Velez, 2013). Cross-linked lacritin has been shown to be inactive (Velez, 2013).  Our ELISA 
does not detect the cross-linked lacritin, as some of the western blot samples with high 
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molecular weight forms of lacritin have undetectable concentrations of lacritin by ELISA. 
This is likely due to the denaturing step of the western blot, which is not performed in the 
ELISA. It is possible that upon crosslinking, the epitope detected by the antibodies must be 
buried and inaccessible. Additionally, two samples on the Set 2 western blot appear to be 
switched; the normal sample has a lacritin concentration of 2 ng and has the absence of the 
band where lacritin should be on the blot, while the dry eye sample has lacritin 
concentration of 14 ng and has a visible band where lacritin should be. It is possible that 
these samples accidently got switched or mislabeled during collection, or during the 
processing done at JMU.  
In conclusion, a system for detecting canine lacritin in canine tear samples was 
developed and used to quantify and visually detect lacritin concentrations. Dye eye samples 
had significantly lower concentrations of lacritin compared to normal samples, reinforcing 
the hypothesis that lacritin replacement may be an effective therapeutic for dry eye.  
Future work to continue this project include both canine and human clinical trials, 
which are both needed to bring a drug to market. As for a canine therapeutic, the next step 
would be to conduct a study in which lacritin is topically applied to the eyes of healthy and 
dry eye dogs to see if it improves basal tearing levels. The ELISA which was developed in 
the study can be used to identify canines with low lacritin levels to enroll in the canine 
clinical studies. This ELSIA can also be used to monitor lacritin levels in the treated canines 
over time to assess the effectiveness of lacritin replacement therapy. Successful treatment 
of canine dry eye with lacritin holds promising results for treating human dry eye. Human 
clinical trials are needed to confirm the efficacy and safety of lacritin as a therapeutic in 
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APPENDIX A  
Raw data from the BCA assay is shown below. A darker shade of orange indicates a higher 
standard deviation of the absorbances. Mathematically, the corrected column represents 
the average absorbance with the background absorbance subtracted out.  
BCA Canine Samples 2-17-16 Set 1 
          
  
ABS 1 ABS 2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
0.986 0.983 0.985 0.002 2.000 0.909 
  
  
0.804 0.757 0.781 0.033 1.500 0.705 
  
  
0.653 0.567 0.610 0.061 1.000 0.535 
  
  
0.484 0.475 0.480 0.006 0.750 0.404 
  
  
0.360 0.348 0.354 0.008 0.500 0.279 
  
  
0.229 0.228 0.229 0.001 0.250 0.153 
  
  
0.156 0.150 0.153 0.004 0.125 0.078 
  
  
0.092 0.095 0.094 0.002 0.025 0.018 
  
  




        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          
          
 
Sample ABS 1 ABS 2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OS 68 0.153 0.158 0.156 0.004 0.080 0.16698 166.98 1002 
 
OD 68 0.171 0.171 0.171 0.000 0.096 0.19933 199.33 1196 
 
OS 43 0.178 0.159 0.169 0.013 0.093 0.19411 194.11 1165 
 
OD 43 0.251 0.243 0.247 0.006 0.172 0.35796 357.96 2148 
 
OS 91 0.185 0.219 0.202 0.024 0.127 0.26404 264.04 1584 
 
OD 91 0.229 0.197 0.213 0.023 0.138 0.28700 287 1722 
 
OS 03 0.172 0.181 0.177 0.006 0.101 0.21081 210.81 1265 
 



















BCA Canine Samples 2-17-16 Set 2 
          
  
ABS 
1 ABS 2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
1.073 1.053 1.063 0.014 2.000 0.988 
  
  
0.839 0.817 0.828 0.016 1.500 0.753 
  
  
0.643 0.579 0.611 0.045 1.000 0.536 
  
  
0.479 0.469 0.474 0.007 0.750 0.399 
  
  
0.351 0.344 0.348 0.005 0.500 0.273 
  
  
0.223 0.230 0.227 0.005 0.250 0.152 
  
  
0.153 0.152 0.153 0.001 0.125 0.078 
  
  
0.091 0.093 0.092 0.001 0.025 0.017 
  
  




        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          




1 ABS 2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 35 0.105 0.107 0.106 0.001 0.031 0.06118 61.18 367.1 
 
OS 35 0.117 0.118 0.118 0.001 0.043 0.08388 83.876 503.3 
 
OD 26 0.170 0.164 0.167 0.004 0.092 0.18157 181.57 1089 
 
OS 26 0.172 0.170 0.171 0.001 0.096 0.18946 189.46 1137 
 
OD 47 0.168 0.151 0.160 0.012 0.085 0.16677 166.77 1001 
 
OS 47 0.153 0.141 0.147 0.008 0.072 0.14210 142.1 852.6 
 
OD 139 0.183 0.182 0.183 0.001 0.108 0.21216 212.16 1273 
 



















          
          
          BCA Canine Samples 2-22-16 Set 3 
          
  
ABS 1 ABS 2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
1.053 1.049 1.051 0.003 2.000 0.974 
  
  
0.823 0.788 0.806 0.025 1.500 0.729 
  
  
0.674 0.583 0.629 0.064 1.000 0.552 
  
  
0.474 0.457 0.466 0.012 0.750 0.389 
  
  
0.350 0.339 0.345 0.008 0.500 0.268 
  
  
0.228 0.222 0.225 0.004 0.250 0.148 
  
  
0.154 0.158 0.156 0.003 0.125 0.079 
  
  
0.094 0.094 0.094 0.000 0.025 0.017 
  
  




        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          
          
 
Sample ABS 1 ABS 2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 37 0.203 0.204 0.204 0.001 0.127 0.25335 253.35 1520 
 
OS 37 0.182 0.182 0.182 0.000 0.105 0.21029 210.29 1262 
 
OD 97 0.690 0.632 0.661 0.041 0.584 1.16964 1169.6 7018 
 
OS 97 0.760 0.668 0.714 0.065 0.637 1.27579 1275.8 7655 
 
OD 82 0.505 0.449 0.477 0.040 0.400 0.80112 801.12 4807 
 
OS 82 0.233 0.216 0.225 0.012 0.148 0.29541 295.41 1772 
 
OD 61 0.329 0.445 0.387 0.082 0.310 0.62087 620.87 3725 
 
OS 61 0.350 0.298 0.324 0.037 0.247 0.49469 494.69 2968 



















BCA Canine Samples 2-22-16 Set 4 
          
  
ABS 1 ABS 2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
1.043 1.058 1.051 0.011 2.000 0.973 
  
  
0.848 0.799 0.824 0.035 1.500 0.746 
  
  
0.683 0.570 0.627 0.080 1.000 0.549 
  
  
0.483 0.465 0.474 0.013 0.750 0.397 
  
  
0.362 0.347 0.355 0.011 0.500 0.277 
  
  
0.235 0.224 0.230 0.008 0.250 0.152 
  
  
0.156 0.156 0.156 0.000 0.125 0.079 
  
  
0.093 0.093 0.093 0.000 0.025 0.016 
  
  




        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          
          
 
Sample ABS 1 ABS 2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 039 0.240 0.245 0.243 0.004 0.165 0.32777 327.77 1967 
 
OS 039 0.171 0.164 0.168 0.005 0.090 0.17878 178.78 1073 
 
OD 18 0.363 0.208 0.286 0.110 0.208 0.41319 413.19 2479 
 
OS 18 0.174 0.160 0.167 0.010 0.090 0.17779 177.79 1067 
 
OD 100 0.192 0.189 0.191 0.002 0.113 0.22447 224.47 1347 
 
OS 100 0.304 0.268 0.286 0.025 0.209 0.41418 414.18 2485 
 
OD 30 0.214 0.222 0.218 0.006 0.141 0.27910 279.1 1675 
 
OS 30 0.190 0.195 0.193 0.004 0.115 0.22845 228.45 1371 



















BCA Canine Samples 2-24-16 SET 5 





2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
0.995 0.993 0.994 0.001 2.000 0.916 
  
  
0.783 0.762 0.773 0.015 1.500 0.695 
  
  
0.672 0.548 0.610 0.088 1.000 0.532 
  
  
0.463 0.488 0.476 0.018 0.750 0.398 
  
  
0.351 0.325 0.338 0.018 0.500 0.260 
  
  
0.225 0.227 0.226 0.001 0.250 0.148 
  
  
0.153 0.156 0.155 0.002 0.125 0.077 
  
  
0.092 0.090 0.091 0.001 0.025 0.013 
  
  




        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          






2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 777 0.202 0.190 0.196 0.008 0.118 0.24754 247.54 1485 
 
OS 777 0.240 0.229 0.235 0.008 0.157 0.32830 328.3 1970 
 
OD 059 0.146 0.137 0.142 0.006 0.064 0.13321 133.21 799.2 
 
OS 059 0.548 0.257 0.403 0.206 0.325 0.68072 680.72 4084 
 
OD 754 0.179 0.181 0.180 0.001 0.102 0.21397 213.97 1284 
 
OS 754 0.167 0.163 0.165 0.003 0.087 0.18250 182.5 1095 
 
OD 303 0.141 0.127 0.134 0.010 0.056 0.11747 117.47 704.8 
 

















          
           
BCA Canine Samples 2-24-16 SET 6 





2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
0.973 0.968 0.971 0.004 2.000 0.916 
  
  
0.782 0.769 0.776 0.009 1.500 0.721 
  
  
0.656 0.521 0.589 0.095 1.000 0.534 
  
  
0.456 0.453 0.455 0.002 0.750 0.400 
  
  
0.330 0.325 0.328 0.004 0.500 0.273 
  
  
0.207 0.208 0.208 0.001 0.250 0.153 
  
  
0.137 0.133 0.135 0.003 0.125 0.081 
  
  
0.070 0.070 0.070 0.000 0.025 0.016 
  
  




        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          






2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 428 0.099 0.099 0.099 0.000 0.045 0.09211 92.113 552.7 
 
OS 428 0.150 0.178 0.164 0.020 0.110 0.22666 226.66 1360 
 
OD 989 0.378 0.384 0.381 0.004 0.327 0.67584 675.84 4055 
 
OS 989 0.271 0.314 0.293 0.030 0.238 0.49265 492.65 2956 
 
OD 897 0.209 0.197 0.203 0.008 0.149 0.30739 307.39 1844 
 
OS 897 0.174 0.175 0.175 0.001 0.120 0.24840 248.4 1490 
 
OD 481 0.161 0.163 0.162 0.001 0.108 0.22252 222.52 1335 
 

















          
           
BCA Canine Samples 2-26-16 SET 7 





2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
1.120 1.095 1.108 0.018 2.000 1.019 
  
  
0.897 0.868 0.883 0.021 1.500 0.794 
  
  
0.671 0.585 0.628 0.061 1.000 0.539 
  
  
0.525 0.511 0.518 0.010 0.750 0.429 
  
  
0.370 0.361 0.366 0.006 0.500 0.277 
  
  
0.241 0.243 0.242 0.001 0.250 0.153 
  
  
0.159 0.158 0.159 0.001 0.125 0.070 
  
  
0.105 0.107 0.106 0.001 0.025 0.017 
  
  




        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          






2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 839 0.187 0.160 0.174 0.019 0.085 0.16098 160.98 965.9 
 
OS 839 0.157 0.158 0.158 0.001 0.069 0.13050 130.5 783 
 
OS 581 0.241 0.233 0.237 0.006 0.148 0.28196 281.96 1692 
 
OS 570 0.181 0.182 0.182 0.001 0.093 0.17622 176.22 1057 
 
OD 478 0.194 0.197 0.196 0.002 0.107 0.20290 202.9 1217 
 
OS 478 0.274 0.208 0.241 0.047 0.152 0.28958 289.58 1737 
 
OD 415 0.246 0.250 0.248 0.003 0.159 0.30291 302.91 1817 
 

















          
           
BCA Canine Samples 2-26-16 SET 8 





2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
0.944 0.982 0.963 0.027 2.000 0.885 
  
  
0.802 0.766 0.784 0.025 1.500 0.706 
  
  
0.631 0.526 0.579 0.074 1.000 0.500 
  
  
0.480 0.448 0.464 0.023 0.750 0.386 
  
  
0.321 0.334 0.328 0.009 0.500 0.249 
  
  
0.208 0.202 0.205 0.004 0.250 0.127 
  
  
0.152 0.150 0.151 0.001 0.125 0.073 
  
  
0.089 0.092 0.091 0.002 0.025 0.012 
  
  




        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          






2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 564 0.215 0.164 0.190 0.036 0.111 0.23897 238.97 1434 
 
OS 185 0.145 0.141 0.143 0.003 0.065 0.13886 138.86 833.2 
 
OD 803 0.186 0.187 0.187 0.001 0.108 0.23251 232.51 1395 
 
OS 803 0.243 0.226 0.235 0.012 0.156 0.33584 335.84 2015 
 
OD 0039 0.180 0.159 0.170 0.015 0.091 0.19591 195.91 1175 
 
OS 0039 0.176 0.150 0.163 0.018 0.085 0.18192 181.92 1091 
 
OD 477 0.166 0.177 0.172 0.008 0.093 0.20022 200.22 1201 
 






















         
 
         
 
APPENDIX B   
Raw data from the ELISA is shown below. Darker shades of orange indicate a higher 
standard deviation in the three absorbances measured from each sample.  
 
 
ng cLac abs 1 abs 2 abs 3 average 
16 0.735 0.719 0.700 0.718
14 0.596 0.622 0.637 0.618
12 0.542 0.524 0.588 0.551
10 0.513 0.528 0.536 0.526
8 0.460 0.469 0.462 0.464
6 0.400 0.394 0.384 0.393
4 0.300 0.312 0.307 0.306
2 0.217 0.214 0.221 0.217
0 0.136 0.062 0.092
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng Dry eye?
OS 68 0.199 0.187 0.203 0.203 0.008 0.901 DE
OD 68 0.697 0.728 0.733 0.733 0.020 16.769 DE
OS 43 0.313 0.327 0.333 0.333 0.010 4.793 DE
OD 43 0.361 0.375 0.362 0.362 0.008 5.662 DE
OS 91 0.293 0.307 0.290 0.290 0.009 3.506 N
OD 91 0.774 0.795 0.748 0.748 0.024 17.219 N
OS 03 0.846 0.821 0.825 0.825 0.013 19.524 N
OD 03 0.327 0.329 0.315 0.315 0.008 4.254 N
Standard Curve 2-18-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)















ng cLac abs 1 abs 2 abs 3 average 
16 0.647 0.673 0.677 0.666
14 0.581 0.596 0.600 0.592
12 0.491 0.507 0.517 0.505
10 0.473 0.486 0.462 0.474
8 0.382 0.395 0.427 0.401
6 0.352 0.368 0.369 0.363
4 0.275 0.294 0.298 0.289
2 0.181 0.189 0.190 0.187
0 0.048 0.049 0.050
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng Dry eye?
OS 68 0.167 0.191 0.162 0.173 0.016 0.823 DE
OD 68 0.652 0.585 0.647 0.628 0.037 15.031 DE
OS 43 0.293 0.279 0.296 0.289 0.009 4.448 DE
OD 43 0.334 0.336 0.329 0.333 0.004 5.813 DE
OS 91 0.274 0.262 0.281 0.272 0.010 3.917 N
OD 91 0.706 0.607 0.650 0.654 0.050 15.854 N
OS 03 0.785 0.772 0.782 0.780 0.007 19.771 N
OD 03 0.259 0.284 0.297 0.280 0.019 4.156 N
Standard Curve 2-18-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)















ng cLac abs 1 abs 2 abs 3 average 
16 0.736 0.696 0.801 0.744
14 0.730 0.657 0.659 0.682
12 0.658 0.651 0.690 0.666
10 0.603 0.668 0.639 0.637
8 0.510 0.542 0.540 0.531
6 0.413 0.459 0.436 0.436
4 0.354 0.363 0.357 0.358
2 0.389 0.395 0.282 0.355
0 0.051 0.056 0.052
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng Dry eye? On treatment?
OD 35 0.356 0.359 0.367 0.361 0.006 2.773 DE Yes
OS 35 0.419 0.446 0.470 0.445 0.026 5.529 DE Yes
OD 26 0.728 0.731 0.717 0.725 0.007 14.691 DE Yes
OS 26 0.563 0.517 0.574 0.551 0.030 9.004 DE Yes
OD 47 0.118 0.117 0.132 0.122 0.008 -5.015 N
OS 47 0.902 0.706 0.935 0.848 0.124 18.688 N
OD 139 0.694 0.725 0.715 0.711 0.016 14.233 N
OS 139 0.757 0.725 0.691 0.724 0.033 14.658 DE Yes
Standard Curve 2-18-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)






















ng cLac abs 1 abs 2 abs 3 average 
16 0.647 0.650 0.673 0.657
14 0.551 0.575 0.606 0.577
12 0.552 0.554 0.607 0.571
10 0.532 0.530 0.555 0.539
8 0.427 0.436 0.477 0.447
6 0.359 0.392 0.398 0.383
4 0.330 0.342 0.349 0.340
2 0.217 0.239 0.239 0.232
0 0.048 0.049 0.054
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng
OD 35 0.299 0.279 0.287 0.288 0.010 3.717
OS 35 0.437 0.419 0.404 0.420 0.017 9.981
OD 26 0.672 0.701 0.691 0.688 0.015 22.731
OS 26 0.540 0.519 0.511 0.523 0.015 14.897
OD 47 0.100 0.097 0.117 0.105 0.011 -5.021
OS 47 0.821 0.857 0.815 0.831 0.023 29.534
OD 139 0.692 0.606 0.607 0.635 0.049 20.209
OS 139 0.680 0.683 0.696 0.686 0.009 22.651
Standard Curve 2-18-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)















ng cLac abs 1 abs 2 abs 3 average 
16 0.685 0.743 0.714 0.714
14 0.591 0.619 0.532 0.581
12 0.538 0.539 0.550 0.542
10 0.512 0.514 0.537 0.521
8 0.449 0.458 0.450 0.452
6 0.386 0.402 0.413 0.400
4 0.284 0.304 0.316 0.301
2 0.183 0.165 0.195 0.181
0 0.068 0.054 0.057
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ng Dry eye? On treatment?
OD 37 0.642 0.614 0.618 0.625 0.015 13.859 N
OS 37 0.903 0.881 0.912 0.899 0.016 22.038 N
OD 97 0.093 0.072 0.088 0.084 0.011 -2.271 DE Yes
OS 97 0.065 0.062 0.065 0.064 0.002 -2.878 DE Yes
OD 82 0.126 0.111 0.097 0.111 0.015 -1.465 DE Yes
OS 82 0.894 0.908 0.835 0.879 0.039 21.451 DE Yes
OD 61 0.058 0.067 0.062 0.062 0.005 -2.927 DE No
OS 61 0.193 0.167 0.144 0.168 0.025 0.227 DE No
Standard Curve 2-18-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)
















ng cLac abs 1 abs 2 abs 3 average 
16 0.693 0.697 0.688 0.693
14 0.570 0.595 0.560 0.575
12 0.496 0.500 0.492 0.496
10 0.496 0.495 0.491 0.494
8 0.438 0.436 0.437
6 0.403 0.391 0.392 0.395
4 0.283 0.284 0.299 0.289
2 0.191 0.197 0.207 0.198
0 0.074 0.075 0.061
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng Dry eye?
OD 37 0.558 0.581 0.599 0.579 0.021 13.014 N
OS 37 0.859 0.911 0.833 0.868 0.040 22.376 N
OD 97 0.100 0.090 0.112 0.101 0.011 -2.527 DE
OS 97 0.074 0.086 0.083 0.081 0.006 -3.166 DE
OD 82 0.107 0.123 0.113 0.114 0.008 -2.083 DE
OS 82 0.922 0.620 0.916 0.819 0.173 20.806 DE
OD 61 0.082 0.082 0.096 0.087 0.008 -2.982 DE
OS 61 0.163 0.147 0.195 0.168 0.024 -0.330 DE
Standard Curve 2-18-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)
















ng cLac abs 1 abs 2 abs 3 average 
16 0.886 0.775 0.867
14 0.662 0.627 0.662 0.650
12 0.582 0.565 0.560 0.569
10 0.515 0.541 0.576 0.544
8 0.479 0.451 0.506 0.479
6 0.401 0.414 0.438 0.418
4 0.397 0.434 0.416 0.416
2 0.281 0.298 0.306 0.295
0 0.059 0.057 0.056
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ng Dry eye? On treatment?
OD 039 0.406 0.412 0.468 0.429 0.034 6.021 DE Yes
OS 039 0.184 0.189 0.199 0.191 0.008 -2.859 DE Yes
OD 18 0.061 0.067 0.071 0.066 0.005 -7.499 DE No
OS 18 0.136 0.129 0.136 0.134 0.004 -4.986 DE No
OD 100 0.656 0.808 0.763 0.742 0.078 17.725 DE No
OS 100 0.846 0.647 0.517 0.670 0.166 15.026 N
OD 30 0.745 0.697 0.740 0.727 0.026 17.165 N
OS 30 0.778 0.649 0.726 0.718 0.065 16.805 N
Standard Curve 2-11-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)















ng cLac abs 1 abs 2 abs 3 average 
16 0.886 0.775 0.867
14 0.662 0.627 0.662 0.650
12 0.582 0.565 0.560 0.569
10 0.515 0.541 0.576 0.544
8 0.479 0.451 0.506 0.479
6 0.401 0.414 0.438 0.418
4 0.397 0.434 0.416 0.416
2 0.281 0.298 0.306 0.295
0 0.059 0.057 0.056
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ng Dry eye? On treatment?
OD 039 0.406 0.412 0.468 0.429 0.034 6.021 DE Yes
OS 039 0.184 0.189 0.199 0.191 0.008 -2.859 DE Yes
OD 18 0.061 0.067 0.071 0.066 0.005 -7.499 DE No
OS 18 0.136 0.129 0.136 0.134 0.004 -4.986 DE No
OD 100 0.656 0.808 0.763 0.742 0.078 17.725 DE No
OS 100 0.846 0.647 0.517 0.670 0.166 15.026 N
OD 30 0.745 0.697 0.740 0.727 0.026 17.165 N
OS 30 0.778 0.649 0.726 0.718 0.065 16.805 N
Standard Curve 2-11-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)
















ng cLac abs 1 abs 2 abs 3 average 
16 0.735 0.719 0.700 0.718
14 0.596 0.622 0.637 0.618
12 0.542 0.524 0.588 0.551
10 0.513 0.528 0.536 0.526
8 0.460 0.469 0.462 0.464
6 0.400 0.394 0.384 0.393
4 0.300 0.312 0.307 0.306
2 0.217 0.214 0.221 0.217
0 0.136 0.062 0.092
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng Dry eye?
OS 68 0.199 0.187 0.203 0.203 0.008 0.901 DE
OD 68 0.697 0.728 0.733 0.733 0.020 16.769 DE
OS 43 0.313 0.327 0.333 0.333 0.010 4.793 DE
OD 43 0.361 0.375 0.362 0.362 0.008 5.662 DE
OS 91 0.293 0.307 0.290 0.290 0.009 3.506 N
OD 91 0.774 0.795 0.748 0.748 0.024 17.219 N
OS 03 0.846 0.821 0.825 0.825 0.013 19.524 N
OD 03 0.327 0.329 0.315 0.315 0.008 4.254 N
Standard Curve 2-18-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)















ng cLac abs 1 abs 2 abs 3 average 
16 1.036 1.031 0.968 1.012
14 0.897 0.869 0.929 0.898
12 0.754 0.742 0.846 0.781
10 0.703 0.706 0.702 0.704
8 0.541 0.524 0.534 0.533
6 0.475 0.473 0.542 0.497
4 0.334 0.340 0.347 0.340
2 0.311 0.225 0.231 0.256
0 0.199 0.047 0.057
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ng Dry eye? On treatment?
OD 428 0.478 0.511 0.563 0.517 0.043 6.966 DE Yes
OS 428 0.185 0.173 0.179 0.179 0.006 0.723 DE Yes
OD 989 1.003 0.692 1.003 0.899 0.180 14.014 DE No
OS 989 1.154 1.141 1.103 1.133 0.027 18.319 DE No
OD 897 1.406 1.326 1.339 1.357 0.043 22.458 N No
OS 897 1.350 1.311 1.303 1.321 0.025 21.800 N No
OD 481 1.201 1.201 1.175 1.192 0.015 19.419 N No
OS 481 1.247 1.201 1.316 1.255 0.058 20.569 N No
Standard Curve 2-11-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)






















ng cLac abs 1 abs 2 abs 3 average 
16 1.022 0.988 1.030 1.013
14 0.833 0.846 0.809 0.829
12 0.752 0.816 0.788 0.785
10 0.701 0.694 0.713 0.703
8 0.562 0.579 0.574 0.572
6 0.509 0.486 0.445 0.480
4 0.345 0.359 0.394 0.366
2 0.230 0.230 0.255 0.238
0 0.059 0.055 0.060
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ng Dry eye? On treatment?
OD 428 0.570 0.553 0.553 0.559 0.010 7.766 DE Yes
OS 428 0.182 0.169 0.199 0.183 0.015 0.590 DE Yes
OD 989 0.984 0.998 0.981 0.988 0.009 15.969 DE No
OS 989 1.178 1.174 1.146 1.166 0.017 19.379 DE No
OD 897 1.406 1.403 1.394 1.401 0.006 23.872 N No
OS 897 1.424 1.322 1.343 1.363 0.054 23.145 N No
OD 481 1.264 1.284 1.218 1.255 0.034 21.087 N No
OS 481 1.288 1.279 1.256 1.274 0.017 21.450 N No
Standard Curve 2-11-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)













ng cLac abs 1 abs 2 abs 3 average 
16 0.647 0.673 0.677 0.666
14 0.581 0.596 0.600 0.592
12 0.491 0.507 0.517 0.505
10 0.473 0.486 0.462 0.474
8 0.382 0.395 0.427 0.401
6 0.352 0.368 0.369 0.363
4 0.275 0.294 0.298 0.289
2 0.181 0.189 0.190 0.187
0 0.048 0.049 0.050
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng Dry eye?
OS 68 0.167 0.191 0.162 0.173 0.016 0.823 DE
OD 68 0.652 0.585 0.647 0.628 0.037 15.031 DE
OS 43 0.293 0.279 0.296 0.289 0.009 4.448 DE
OD 43 0.334 0.336 0.329 0.333 0.004 5.813 DE
OS 91 0.274 0.262 0.281 0.272 0.010 3.917 N
OD 91 0.706 0.607 0.650 0.654 0.050 15.854 N
OS 03 0.785 0.772 0.782 0.780 0.007 19.771 N
OD 03 0.259 0.284 0.297 0.280 0.019 4.156 N
Standard Curve 2-18-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)















ng cLac abs 1 abs 2 abs 3 average 
16 0.702 0.730 0.783 0.738
14 0.674 0.691 0.695 0.687
12 0.543 0.538 0.588 0.556
10 0.581 0.556 0.576 0.571
8 0.532 0.522 0.522 0.525
6 0.468 0.432 0.443 0.448
4 0.360 0.379 0.382 0.374
2 0.265 0.266 0.278 0.270
0 0.058 0.062 0.059
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ng Dry eye? On treatment?
OD 839 0.489 0.415 0.512 0.472 0.051 7.408 DE Yes
OS 839 0.633 0.657 0.659 0.650 0.014 13.121 DE Yes
OS 581 0.364 0.372 0.392 0.376 0.014 4.322 DE No
OS 570 0.731 0.747 0.751 0.743 0.011 16.122 N No
OD 478 0.749 0.761 0.756 0.755 0.006 16.519 N No
OS 478 0.638 0.669 0.662 0.656 0.016 13.335 N No
OD 415 0.975 0.991 1.029 0.998 0.028 24.332 N No
OS 415 0.959 0.946 0.996 0.967 0.026 23.325 N No
Standard Curve 2-18-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)















ng cLac abs 1 abs 2 abs 3 average 
16 0.772 0.779 0.812 0.788
14 0.684 0.714 0.730 0.709
12 0.577 0.638 0.623 0.613
10 0.577 0.603 0.654 0.611
8 0.548 0.540 0.612 0.567
6 0.477 0.467 0.470 0.471
4 0.373 0.367 0.383 0.374
2 0.262 0.288 0.281 0.277
0 0.052 0.051 0.051
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ng Dry eye? On treatment?
OD 839 0.521 0.498 0.560 0.526 0.031 8.275 DE Yes
OS 839 0.691 0.725 0.727 0.714 0.020 13.804 DE Yes
OS 581 0.360 0.401 0.377 0.379 0.021 3.951 DE No
OS 570 0.750 0.737 0.735 0.741 0.008 14.578 N No
OD 478 0.806 0.786 0.780 0.791 0.014 16.049 N No
OS 478 0.703 0.630 0.665 0.666 0.037 12.382 N No
OD 415 1.065 1.091 1.077 1.078 0.013 24.490 N No
OS 415 1.012 0.993 0.985 0.997 0.014 22.108 N No
Standard Curve 2-18-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)
















ng cLac abs 1 abs 2 abs 3 average 
16 0.705 0.747 0.758 0.737
14 0.760 0.773 0.802 0.778
12 0.684 0.746 0.766 0.732
10 0.696 0.714 0.721 0.710
8 0.613 0.632 0.628 0.624
6 0.565 0.536 0.542 0.548
4 0.457 0.490 0.484 0.477
2 0.308 0.333 0.337 0.326
0 0.051 0.058 0.057
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng Dry eye? On treatment?
OD 564 0.420 0.438 0.468 0.442 0.013 3.157 DE Y
OS 183 0.378 0.365 0.390 0.378 0.013 1.006 DE N
OD 803 0.681 0.699 0.756 0.712 0.074 12.187 N
OS 803 0.741 0.829 0.769 0.780 0.049 14.450 N
OD 0039 0.718 0.674 0.651 0.681 0.062 11.151 N
OS 0039 0.848 0.774 0.813 0.812 0.070 15.521 N
OD 477 0.952 0.948 0.923 0.941 0.052 19.846 N
OS 477 0.865 0.851 0.814 0.843 0.036 16.580 N
Standard Curve 2-29-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)
























ng cLac abs 1 abs 2 abs 3 average 
16 0.695 0.754 0.766 0.738
14 0.757 0.768 0.840 0.788
12 0.687 0.676 0.759 0.707
10 0.654 0.697 0.724 0.692
8 0.638 0.625 0.765 0.676
6 0.569 0.528 0.569 0.555
4 0.461 0.486 0.492 0.480
2 0.336 0.351 0.355 0.347
0 0.050 0.06 0.058
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ng Dry eye? On treatment?
OD 564 0.476 0.433 0.498 0.469 0.033 3.555 DE Y
OS 183 0.404 0.392 0.410 0.402 0.009 1.187 DE N
OD 803 0.808 0.769 0.741 0.773 0.034 14.285 N
OS 803 0.806 0.803 0.848 0.819 0.025 15.922 N
OD 0039 0.771 0.786 0.777 0.778 0.008 14.473 N
OS 0039 0.848 0.843 0.793 0.828 0.030 16.240 N
OD 477 0.968 1.007 0.889 0.955 0.060 20.716 N
OS 477 0.969 0.862 0.835 0.889 0.071 18.384 N
Standard Curve 2-29-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)
















ng cLac abs 1 abs 2 abs 3 average 
16 0.707 0.736 0.748 0.730
14 0.637 0.671 0.630 0.646
12 0.528 0.593 0.716 0.612
10 0.537 0.573 0.583 0.564
8 0.535 0.526 0.532 0.531
6 0.445 0.447 0.459 0.450
4 0.342 0.336 0.342 0.340
2 0.229 0.238 0.244 0.237
0 0.058 0.054 0.054
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng Dry eye? On treatment?
OD 35 0.146 0.111 0.109 0.122 0.025 -2.960 DE Y
OS 35 0.112 0.099 0.088 0.100 0.012 -3.641 DE Y
OD 26 0.477 0.456 0.460 0.464 0.021 7.477 DE Y
OS 26 0.456 0.502 0.465 0.474 0.272 7.782 DE Y
OD 47 0.925 0.931 0.867 0.908 0.325 20.993 N
OS 47 0.341 0.336 0.308 0.328 0.066 3.330 N
OD 139 0.219 0.213 0.177 0.203 0.176 -0.491 N
OS 139 0.597 0.500 0.573 0.557 0.017 10.292 DE Y
OD 747 0.903 0.89 0.897 0.897 0.004 20.658 N
OS 747 0.695 0.704 0.661 0.687 0.024 14.255 N
OD 415 0.857 0.81 0.763 0.810 0.066 18.015 N
Standard Curve 2-29-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)
















ng cLac abs 1 abs 2 abs 3 average 
16 0.804 0.786 0.829 0.806
14 0.667 0.732 0.698 0.699
12 0.621 0.674 0.709 0.668
10 0.584 0.574 0.607 0.588
8 0.528 0.534 0.597 0.553
6 0.459 0.415 0.440 0.438
4 0.349 0.359 0.370 0.359
2 0.245 0.27 0.267 0.261
0 0.050 0.052 0.051
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ngDry eye? On treatment?
OD 35 0.127 0.108 0.115 0.117 0.010 -2.565 DE Y
OS 35 0.100 0.083 0.093 0.092 0.009 -3.228 DE Y
OD 26 0.385 0.423 0.484 0.431 0.050 5.875 DE Y
OS 26 0.447 0.459 0.466 0.457 0.010 6.592 DE Y
OD 47 1.048 0.975 0.943 0.989 0.054 20.875 N
OS 47 0.348 0.337 0.321 0.335 0.014 3.313 N
OD 139 0.208 0.195 0.215 0.206 0.010 -0.164 N
OS 139 0.579 0.530 0.533 0.547 0.027 9.012 DE Y
OD 747 0.963 0.907 0.921 0.930 0.029 19.307 N
OS 747 0.736 0.675 0.721 0.711 0.032 13.402 N
OD 415 0.896 0.8 0.794 0.830 0.057 16.610 N
Standard Curve 2-29-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)

















ng cLac abs 1 abs 2 abs 3 average 
16 0.779 0.836 0.830 0.815
14 0.733 0.750 0.808 0.764
12 0.646 0.648 0.781 0.692
10 0.636 0.692 0.746 0.691
8 0.601 0.606 0.599 0.602
6 0.522 0.509 0.553 0.528
4 0.379 0.391 0.398 0.389
2 0.362 0.379 0.287 0.343
0 0.157 0.050 0.054
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng Dry eye? On treatment?
OD 564 0.351 0.378 0.336 0.355 0.019 1.764 DE Y
OS 185 0.170 0.161 0.172 0.168 0.006 -3.698 DE N
OD 803 0.660 0.671 0.674 0.668 0.066 10.899 N
OS 803 0.748 0.780 0.724 0.751 0.049 13.299 N
OD 0039 0.702 0.654 0.634 0.663 0.060 10.753 N
OS 0039 0.788 0.753 0.751 0.764 0.083 13.688 N
OD 477 1.010 0.910 0.918 0.946 0.123 18.994 N
OS 477 0.838 0.767 0.787 0.797 0.036 14.660 N
OD 100 0.43 0.416 0.403 0.416 0.019 3.552 DE N
OS 303 0.253 0.255 0.258 0.255 0.004 -1.142 N
Standard Curve 2-29-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)

















ng cLac abs 1 abs 2 abs 3 average 
16 0.863 0.866 0.918 0.882
14 0.775 0.811 0.825 0.804
12 0.689 0.735 0.727 0.717
10 0.692 0.691 0.695 0.693
8 0.627 0.646 0.627 0.633
6 0.515 0.522 0.529 0.522
4 0.395 0.419 0.425 0.413
2 0.279 0.281 0.296 0.285
0 0.049 0.052 0.051
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ng Dry eye? On treatment?
OD 564 0.344 0.304 0.314 0.321 0.021 1.615 DE Y
OS 185 0.177 0.167 0.179 0.174 0.006 -2.017 DE N
OD 803 0.678 0.639 0.714 0.677 0.038 10.457 N
OS 803 0.744 0.781 0.736 0.754 0.024 12.359 N
OD 0039 0.675 0.666 0.636 0.659 0.020 10.010 N
OS 0039 0.733 0.641 0.707 0.694 0.047 10.870 N
OD 477 0.922 0.883 0.889 0.898 0.021 15.940 N
OS 477 0.777 0.801 0.779 0.786 0.013 13.153 N
OD 100 0.386 0.413 0.377 0.392 0.019 3.385 DE N
OS 303 0.243 0.238 0.222 0.234 0.011 -0.528 N
Standard Curve 2-29-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)
















ng cLac abs 1 abs 2 abs 3 average 
16 0.793 0.781 0.808 0.794
14 0.670 0.688 0.688 0.682
12 0.557 0.587 0.607 0.584
10 0.556 0.551 0.600 0.569
8 0.530 0.542 0.593 0.555
6 0.434 0.439 0.466 0.446
4 0.309 0.334 0.350 0.331
2 0.229 0.243 0.245 0.239
0 0.052 0.051 0.054
Sample ABS 1 ABS 2 ABS 3 AVG ST DEV ng per 50 ng Dry eye? On treatment?
OS 35 0.265 0.250 0.271 0.262 0.011 1.717 DE Y
OD 139 0.294 0.262 0.291 0.282 0.018 2.281 N
OS 139 0.671 0.679 0.755 0.702 0.110 13.897 DE Y
OD 826 0.542 0.537 0.519 0.533 0.090 9.215 DE Y
OS 826 0.412 0.376 0.383 0.390 0.084 5.272 DE Y
OD 100 0.577 0.540 0.542 0.553 0.048 9.778 DE N
OS 303 0.668 0.637 0.625 0.643 0.122 12.281 N
OD 415 0.860 0.855 0.800 0.838 0.042 17.682 N
OD 747 0.74 0.71 0.654 0.701 0.061 13.887 N
OS 747 0.535 0.51 0.531 0.525 0.003 9.012 N
Standard Curve 2-29-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)





















ng cLac abs 1 abs 2 abs 3 average 
16 0.882 0.941 0.907 0.910
14 0.785 0.765 0.801 0.784
12 0.698 0.681 0.690 0.690
10 0.614 0.609 0.652 0.625
8 0.629 0.608 0.630 0.622
6 0.514 0.517 0.512 0.514
4 0.392 0.399 0.405 0.399
2 0.287 0.283 0.282 0.284
0 0.054 0.053 0.052
Sample ABS 1 ABS 2 ABS 3 AVG ST DEVng per 50 ng Dry eye? On treatment?
OS 35 0.295 0.284 0.287 0.289 0.006 1.262 DE Y
OD 139 0.326 0.336 0.339 0.334 0.007 2.368 N
OS 139 0.789 0.831 0.800 0.807 0.022 13.989 DE Y
OD 826 0.598 0.604 0.573 0.592 0.016 8.707 DE Y
OS 826 0.444 0.474 0.437 0.452 0.020 5.267 DE Y
OD 100 0.649 0.639 0.608 0.632 0.021 9.698 DE N
OS 303 0.727 0.708 0.663 0.699 0.033 11.352 N
OD 415 0.920 0.930 0.876 0.909 0.029 16.495 N
OD 747 0.794 0.79 0.734 0.773 0.034 13.154 N
OS 747 0.601 0.602 0.603 0.602 0.001 8.961 N
Standard Curve 2-29-16: cLAC 1/22/16, 6924 FB PANT (1:6400), Secondary (1:1200)
















Below is the presentation that will be given at the ISAT Senior Symposium on April 15th, 
2016.  
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